Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004

Antiviral Therapy

Volumn 13, Issue SUPPL. 2, 2008, Pages 101-107

  Pillay, Visva ^a   Ledwaba, Johanna ^a   Hunt, Gillian ^a   Rakgotho, Mpho ^a   Singh, Beverly ^a   Makubalo, Lindiwe ^b   Bennett, Diane E ^c   Puren, Adrian ^a   Morris, Lynn ^a  

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b Department of Health ^*  (South Africa)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE; RNA DIRECTED DNA POLYMERASE; VIRUS RNA; P16 PROTEASE, HUMAN IMMUNODEFICIENCY VIRUS 1; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; ARTICLE; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NONHUMAN; PHYLOGENY; PREGNANT WOMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEROPREVALENCE; SOUTH AFRICA; WILD TYPE; WORLD HEALTH ORGANIZATION; ADOLESCENT; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; DISEASE TRANSMISSION; ENZYMOLOGY; GENETICS; HEALTH CARE QUALITY; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMMUNOLOGY; MULTICENTER STUDY; POLYMERASE CHAIN REACTION; PREGNANCY; PRENATAL CARE; PUBLIC HEALTH; RETROSPECTIVE STUDY; STATISTICS; TIME; TREATMENT OUTCOME; VIROLOGY;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV SEROPREVALENCE; HIV-1; HUMANS; NATIONAL HEALTH PROGRAMS; POLYMERASE CHAIN REACTION; POPULATION SURVEILLANCE; PREGNANCY; PRENATAL CARE; PROGRAM EVALUATION; RETROSPECTIVE STUDIES; SOUTH AFRICA; TIME FACTORS; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

EID: 45749155787     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Weinstock HS, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1 infected persons in 10 US cities. J Infect Dis 2004; 189:2174-2180.
2. Wensing AMI, van de Vijver DA, Angarano G, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192:958-966.
3. Soares MA, Brindeiro RM, Tanuri A. Primary HIV-1 drug resistance in Brazil. AIDS 2004; 18:S9-S13.
4. UNAIDS (2006). UNAIDS 2006 Report on the global AIDS epidemic, Annex 2: HIV/AIDS estimates and data, 2005. Available at: http://www.unaids.org
5. Republic of South Africa: Progress Report on Declaration of Commitment on HIV and AIDS 2005. Available at: http://www.doh.gov.za/docs/index.html
6. Guay LA, Musoke P, Fleming T et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:795-802.
7. Martinson N, Morris L, Gray G, et al. HIV resistance and transmission following single dose nevirapine in a PMTCT cohort. 11th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2004, San Francisco, CA, USA. Abstract 38.
8. Loubser S, Balfe P, Sherman G et al. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS 2006; 20:995-1002.
9. Palmer S, Boltz V, Martinson N, et al. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci U S A 2006; 103:7094-7099.
10. Johnson JA, Li JF, Morris L, et al. Emergence of drug-resistant HIV-1 following intrapartum single-dose nevirapine is substantially underestimated. J Inf Dis 2005; 192:16-23.
11. National HIV and Syphilis Antenatal sero-prevalence survey in South Africa 2005. Available at: http://www.doh.gov.za/docs/index.html.
12. Bennett DE, Myatt M, Bertagnolio S et al. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 2008; 13 Suppl 2:15-23.
13. Shafer RW, Rhee SY, Pillay D, et al. HIV-1 RT and protease mutations for HIV-1 drug resistance surveillance. AIDS 2007; 21:215-223.
14. Morris L, Martinson N, Pillay C, et al. Persistence of nevirapine resistance mutations 6 months following single dose nevirapine. XV International AIDS Conference, 2004. 11-16 July 2004, Bangkok, Thailand. Abstract ThOrB1353.